Of the 1531 pairs of propensity score-matched patients, in 59% (908/1531) of the pairs, both members of the pair had 6-year heart failure Review
8 percent) with digoxin and 1194 deaths (35
During follow-up with a mean length of 37 months, 102 patients (21%) in the digoxin group and 119 patients (24%) in the placebo group (hazard ratio [HR], 0
It is the only oral inotrope that does not increase long-term mortality in chronic heart failure and has few side effects when dosed appropriately on the basis of serum concentration
Abstract Background Digoxin acutely increases cardiac output in patients with pulmonary arterial hypertension (PAH) and right ventricular failure; however, the effects
Current guidelines suggest digoxin as an adjunct to optimal medical therapy for symptomatic improvement in CHF
The mortality excess with digoxin decreased from 66% without any covariates present to 41% with adjustments for covariates (including propensity scores)
25) with moderate certainty of
Among 91
The present systematic review and meta-analysis of all available data sources suggest that digoxin use is associated with an increased mortality risk, particularly among patients suffering from AF
We aimed to assess the risk of mortality and clinical effects of digoxin use in patients with AF
The effect of digoxin on mortality and Methods and results
Digoxin Oral Solution USP is indicated for the treatment of mild to moderate heart failure
9 ng/mL, is recommended for patients with HF who are taking digoxin
The independent association between digoxin use and patient characteristics was assessed by logistic regression, and between digoxin use and outcomes [composite of all-cause mortality or HF hospitalization (HFH), all-cause
identified a 25% increased risk of mortality in patients with atrial fibrillation taking digoxin
Introduction
8 ng/ml) and increased mortality among patients with levels >1
Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate congestive heart failure: results of the PROVED trial
Angiotensin converting enzyme (ACE) inhibitors